Results 61 to 70 of about 1,581,172 (300)

High constant incidence of second primary colorectal cancer [PDF]

open access: yes, 2013
Patients who had a colorectal cancer have a 1.5- to 2-fold excess risk of a second colorectal cancer as compared to the general population, the excess being higher at younger age at diagnosis.
La Vecchia, Carlo   +13 more
core   +1 more source

Clinical characteristics of second primary pancreatic cancer.

open access: yesPLoS ONE, 2017
PurposeSeveral studies reported the increased risk of second primary pancreatic ductal adenocarcinoma (2nd PDAC) in cancer survivors. However, data on the characteristics of 2nd PDAC are insufficient.MethodsThis retrospective cohort study included 1759 ...
Jung Hyun Jo   +9 more
doaj   +1 more source

Enteropathogenic E. coli shows delayed attachment and host response in human jejunum organoid‐derived monolayers compared to HeLa cells

open access: yesFEBS Letters, EarlyView.
Enteropathogenic E. coli (EPEC) infects the human intestinal epithelium, resulting in severe illness and diarrhoea. In this study, we compared the infection of cancer‐derived cell lines with human organoid‐derived models of the small intestine. We observed a delayed in attachment, inflammation and cell death on primary cells, indicating that host ...
Mastura Neyazi   +5 more
wiley   +1 more source

Second primary cancers in people who had cancer as children: an Australian Childhood Cancer Registry population-based study [PDF]

open access: yes, 2019
Objective: To investigate the incidence of second primary cancers in people diagnosed with cancer during childhood. Design, setting: Retrospective, population-based study; analysis of Australian Childhood Cancer Registry data.
Baade, Peter D.   +11 more
core   +1 more source

Organoids in pediatric cancer research

open access: yesFEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Risk of second primary cancers in women diagnosed with endometrial cancer in German and Swedish cancer registries [PDF]

open access: yes, 2017
Along with the increasing incidence and favorable prognosis, more women diagnosed with endometrial cancer may develop second primary cancers (SPCs). We aimed at investigating risk of SPCs after endometrial cancer in Germany and Sweden to provide insight ...
Kari Hemminki   +41 more
core   +1 more source

Role of chemotherapy for survival in patients with second primary non‐small cell lung cancer

open access: yesThoracic Cancer, 2021
Background The therapeutic effect of chemotherapy is still unclear for clinical usage among second primary non‐small cell lung cancer (NSCLC) patients. The aim of this study was to verify the therapeutic effect of chemotherapy and identify the prognostic
Zhile Wang   +6 more
doaj   +1 more source

Characteristics of second primary breast cancer after ovarian cancer: a Korea central cancer registry retrospective study

open access: yesFrontiers in Oncology, 2023
BackgroundSecond primary cancer has become an important issue among cancer survivors. This study sought to determine the differences in clinicopathologic outcomes between second primary breast cancer (SPBC) after ovarian cancer and primary breast cancer (
Eun-Gyeong Lee   +10 more
doaj   +1 more source

Spatiotemporal and quantitative analyses of phosphoinositides – fluorescent probe—and mass spectrometry‐based approaches

open access: yesFEBS Letters, EarlyView.
Fluorescent probes allow dynamic visualization of phosphoinositides in living cells (left), whereas mass spectrometry provides high‐sensitivity, isomer‐resolved quantitation (right). Their synergistic use captures complementary aspects of lipid signaling. This review illustrates how these approaches reveal the spatiotemporal regulation and quantitative
Hiroaki Kajiho   +3 more
wiley   +1 more source

Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. [PDF]

open access: yes, 2009
If breast cancers arise independently in each breast the odds ratio (OR) for bilateral breast cancer for carriers of CHEK2 1100delC should be approximately 5.5, the square of the reported OR for a first primary (OR, 2.34).
Blomqvist, Carl,   +52 more
core   +1 more source

Home - About - Disclaimer - Privacy